Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-11
2009-02-03
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S414000
Reexamination Certificate
active
07485652
ABSTRACT:
The invention relates to compounds of formula (I):and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.
REFERENCES:
patent: 6472386 (2002-10-01), Kodama et al.
patent: 1583249 (1981-01-01), None
patent: 9095482 (1997-08-01), None
patent: WO9719311 (1997-05-01), None
patent: WO02092084 (2002-11-01), None
patent: WO2004006922 (2004-01-01), None
Bennett et al. (Exp. Opin. Ther. Patents 2006, 16(12), 1673-1699).
Geyeregger et al. (Cell. Mol. Life Sci. 2006, 63, 524-539).
Michael et al. (Mini-Reviews in Med. Chem. 2005, 5, 729-740).
Wang et al. Journal of Lipid Research 2005, 46, 2377-2387.
Fluhr et al. The Journal of Investigative Dermatology 2005, 125, 1206-1214.
Lund et al. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23, 1169-1177.
HHMI Bulletin, Sep. 2003.
Willy et al., Genes Dev. 1995, 9:1033-45.
Song et al., Proc Natl Acad Sci USA.1994, 91:10809-13.
Miller Ne., Lipids 1978,13:914-9.
Gordon et al., Am J Med. 1977, 62:707-14.
Lund et al., Arterioscler. Thromb. Vasc. Biol. 2003, 23:1169-77.
Joseph and Tontonoz, Curr. Opin. Pharmacol. 2003, 3:192-7.
Cao et al., J Biol Chem. 2003, 278:1131-6.
Chini et al., J. Org. Chem., 1991, 56(20) 5939-5942.
Duran Pachon et al., Tet. Lett., 2003, 44(32) 6025-6027.
Sundermeyer et al., Chemistry an European Journal, 2003, 9(8), 1828-1836.
Brown et al., Tet. Lett., 2001, 2 (6), 983-985.
Kanekiyo et al., Heterocycles, 2000, 53 (9), 1877-1880.
Pearlstein et al., Bioorg. and Med. Chem. Lett., 2003, 13, 1829-1835.
Mewshaw et al., Bioorg. and Med. Chem. Lett., 2002, 12, 307-310.
Sakagani et al., Synlett. 1996, 163-164.
Maryanoff et al., Chem. Rev., 1989, 89, 863-927.
Saravan et al., Tet. Lett. 1998, 39 (22), 3823-3824.
Togo et al., Syn. Lett., 2003, 702-704.
Durley et al., J. Med. Chem., 2002, 45, 18, 3891-3904.
Tian et al., Org. Lett., 3, 12, 2001, 1929-1932.
Cynkowski et al., J. Chem. Soc. Chem. Commun., 1995, 2335-2336.
Faul et al., Heterocycles, 2001, 55 (4), 689-704.
Olofsson et al. J. Org. Chem., 1998, 65 (15), 5076-5079.
Buchwald et al., J. Org. Chem., 2000, 65 ( 4), 1158-1174.
Takagi et al., Chem. Lett., 1989, 11, 1957-58.
Bennett, D.J., et al., Expert Opin. Ther. Patents, vol. 14, No. 7, pp. 967-982 (2004), XP002342352.
Dehmlow Henrietta
Kuhn Bernd
Panday Narendra
Ratni Hasane
Schulz-Gasch Tanja
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Nolan Jason
Saeed Kamal A
LandOfFree
Indolyl derivatives as liver-X-receptor (LXR) modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolyl derivatives as liver-X-receptor (LXR) modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl derivatives as liver-X-receptor (LXR) modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075348